Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Value assessment of immuno-oncology in the treatment of rare tumors in the era of accelerated conditional approvals.

Lanitis T, Ambavane A, Zheng Y, Schlichting M, Phatak H.

Future Oncol. 2019 Dec;15(35):4057-4067. doi: 10.2217/fon-2019-0456. Epub 2019 Nov 5.

PMID:
31687852
2.

Neuron-specific knockouts indicate the importance of network communication to Drosophila rhythmicity.

Schlichting M, Díaz MM, Xin J, Rosbash M.

Elife. 2019 Oct 15;8. pii: e48301. doi: 10.7554/eLife.48301.

3.

Light-Mediated Circuit Switching in the Drosophila Neuronal Clock Network.

Schlichting M, Weidner P, Diaz M, Menegazzi P, Dalla Benetta E, Helfrich-Förster C, Rosbash M.

Curr Biol. 2019 Oct 7;29(19):3266-3276.e3. doi: 10.1016/j.cub.2019.08.033. Epub 2019 Sep 26.

4.

Psychometric Properties of EQ-5D-5L Scoring Algorithms for the United Kingdom in Metastatic Merkel Cell Carcinoma.

Bharmal M, Hunger M, Schlichting M.

Value Health. 2019 Oct;22(10):1170-1177. doi: 10.1016/j.jval.2019.05.010. Epub 2019 Aug 1.

PMID:
31563260
5.

Predictability Changes What We Remember in Familiar Temporal Contexts.

Kim H, Schlichting ML, Preston AR, Lewis-Peacock JA.

J Cogn Neurosci. 2020 Jan;32(1):124-140. doi: 10.1162/jocn_a_01473. Epub 2019 Sep 27.

6.

Assessment-Schedule Matching in Unanchored Indirect Treatment Comparisons of Progression-Free Survival in Cancer Studies.

Kapetanakis V, Prawitz T, Schlichting M, Ishak KJ, Phatak H, Kearney M, Stevens JW, Benedict A, Bharmal M.

Pharmacoeconomics. 2019 Dec;37(12):1537-1551. doi: 10.1007/s40273-019-00831-3.

PMID:
31555968
7.

Progress update from the hippocampal subfields group.

Olsen RK, Carr VA, Daugherty AM, La Joie R, Amaral RSC, Amunts K, Augustinack JC, Bakker A, Bender AR, Berron D, Boccardi M, Bocchetta M, Burggren AC, Chakravarty MM, Chételat G, de Flores R, DeKraker J, Ding SL, Geerlings MI, Huang Y, Insausti R, Johnson EG, Kanel P, Kedo O, Kennedy KM, Keresztes A, Lee JK, Lindenberger U, Mueller SG, Mulligan EM, Ofen N, Palombo DJ, Pasquini L, Pluta J, Raz N, Rodrigue KM, Schlichting ML, Lee Shing Y, Stark CEL, Steve TA, Suthana NA, Wang L, Werkle-Bergner M, Yushkevich PA, Yu Q, Wisse LEM; Hippocampal Subfields Group.

Alzheimers Dement (Amst). 2019 Jun 13;11:439-449. doi: 10.1016/j.dadm.2019.04.001. eCollection 2019 Dec.

8.

Correction to: Psychometric properties of the FACT-M questionnaire in patients with Merkel cell carcinoma.

Bharmal M, Fofana F, Barbosa CD, Williams P, Mahnke L, Marrel A, Schlichting M.

Health Qual Life Outcomes. 2019 Mar 27;17(1):52. doi: 10.1186/s12955-019-1122-0.

9.

Performance of semi-automated hippocampal subfield segmentation methods across ages in a pediatric sample.

Schlichting ML, Mack ML, Guarino KF, Preston AR.

Neuroimage. 2019 May 1;191:49-67. doi: 10.1016/j.neuroimage.2019.01.051. Epub 2019 Feb 5.

PMID:
30731245
10.

Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma.

D'Angelo SP, Hunger M, Brohl AS, Nghiem P, Bhatia S, Hamid O, Mehnert JM, Terheyden P, Shih KC, Brownell I, Lebbé C, Lewis KD, Linette GP, Milella M, Schlichting M, Hennessy MH, Bharmal M.

Cancer Immunol Immunother. 2019 Apr;68(4):609-618. doi: 10.1007/s00262-018-02295-4. Epub 2019 Feb 5.

11.

A Distinct Visual Pathway Mediates High-Intensity Light Adaptation of the Circadian Clock in Drosophila.

Schlichting M, Menegazzi P, Rosbash M, Helfrich-Förster C.

J Neurosci. 2019 Feb 27;39(9):1621-1630. doi: 10.1523/JNEUROSCI.1497-18.2018. Epub 2019 Jan 3.

12.

Allatostatin-C/AstC-R2 Is a Novel Pathway to Modulate the Circadian Activity Pattern in Drosophila.

Díaz MM, Schlichting M, Abruzzi KC, Long X, Rosbash M.

Curr Biol. 2019 Jan 7;29(1):13-22.e3. doi: 10.1016/j.cub.2018.11.005. Epub 2018 Dec 13.

13.

The ontogeny of memory persistence and specificity.

Ramsaran AI, Schlichting ML, Frankland PW.

Dev Cogn Neurosci. 2019 Apr;36:100591. doi: 10.1016/j.dcn.2018.09.002. Epub 2018 Sep 29. Review.

14.

Cryptochrome Interacts With Actin and Enhances Eye-Mediated Light Sensitivity of the Circadian Clock in Drosophila melanogaster.

Schlichting M, Rieger D, Cusumano P, Grebler R, Costa R, Mazzotta GM, Helfrich-Förster C.

Front Mol Neurosci. 2018 Jul 18;11:238. doi: 10.3389/fnmol.2018.00238. eCollection 2018.

15.

Ventromedial Prefrontal Cortex Is Necessary for Normal Associative Inference and Memory Integration.

Spalding KN, Schlichting ML, Zeithamova D, Preston AR, Tranel D, Duff MC, Warren DE.

J Neurosci. 2018 Apr 11;38(15):3767-3775. doi: 10.1523/JNEUROSCI.2501-17.2018. Epub 2018 Mar 19.

16.

Hippocampal representations as a function of time, subregion, and brain state.

Duncan KD, Schlichting ML.

Neurobiol Learn Mem. 2018 Sep;153(Pt A):40-56. doi: 10.1016/j.nlm.2018.03.006. Epub 2018 Mar 10. Review.

PMID:
29535044
17.

Psychometric properties of the FACT-M questionnaire in patients with Merkel cell carcinoma.

Bharmal M, Fofana F, Barbosa CD, Williams P, Mahnke L, Marrel A, Schlichting M.

Health Qual Life Outcomes. 2017 Dec 22;15(1):247. doi: 10.1186/s12955-017-0815-5. Review. Erratum in: Health Qual Life Outcomes. 2019 Mar 27;17(1):52.

18.

Nonprogression with avelumab treatment associated with gains in quality of life in metastatic Merkel cell carcinoma.

Kaufman HL, Hunger M, Hennessy M, Schlichting M, Bharmal M.

Future Oncol. 2018 Feb;14(3):255-266. doi: 10.2217/fon-2017-0470. Epub 2017 Dec 8.

19.

A New Rhodopsin Influences Light-dependent Daily Activity Patterns of Fruit Flies.

Kistenpfennig C, Grebler R, Ogueta M, Hermann-Luibl C, Schlichting M, Stanewsky R, Senthilan PR, Helfrich-Förster C.

J Biol Rhythms. 2017 Oct;32(5):406-422. doi: 10.1177/0748730417721826. Epub 2017 Aug 25.

PMID:
28840790
20.

Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study.

Apolo AB, Infante JR, Balmanoukian A, Patel MR, Wang D, Kelly K, Mega AE, Britten CD, Ravaud A, Mita AC, Safran H, Stinchcombe TE, Srdanov M, Gelb AB, Schlichting M, Chin K, Gulley JL.

J Clin Oncol. 2017 Jul 1;35(19):2117-2124. doi: 10.1200/JCO.2016.71.6795. Epub 2017 Apr 4.

21.

Adaptation of Circadian Neuronal Network to Photoperiod in High-Latitude European Drosophilids.

Menegazzi P, Dalla Benetta E, Beauchamp M, Schlichting M, Steffan-Dewenter I, Helfrich-Förster C.

Curr Biol. 2017 Mar 20;27(6):833-839. doi: 10.1016/j.cub.2017.01.036. Epub 2017 Mar 2.

22.

A Neural Network Underlying Circadian Entrainment and Photoperiodic Adjustment of Sleep and Activity in Drosophila.

Schlichting M, Menegazzi P, Lelito KR, Yao Z, Buhl E, Dalla Benetta E, Bahle A, Denike J, Hodge JJ, Helfrich-Förster C, Shafer OT.

J Neurosci. 2016 Aug 31;36(35):9084-96. doi: 10.1523/JNEUROSCI.0992-16.2016.

23.

Hippocampal Structure Predicts Statistical Learning and Associative Inference Abilities during Development.

Schlichting ML, Guarino KF, Schapiro AC, Turk-Browne NB, Preston AR.

J Cogn Neurosci. 2017 Jan;29(1):37-51. Epub 2016 Aug 30.

24.

Hippocampal-medial prefrontal circuit supports memory updating during learning and post-encoding rest.

Schlichting ML, Preston AR.

Neurobiol Learn Mem. 2016 Oct;134 Pt A:91-106. doi: 10.1016/j.nlm.2015.11.005. Epub 2015 Nov 25.

25.

Normal vision can compensate for the loss of the circadian clock.

Schlichting M, Menegazzi P, Helfrich-Förster C.

Proc Biol Sci. 2015 Sep 22;282(1815). pii: 20151846. doi: 10.1098/rspb.2015.1846.

26.
27.

Twilight dominates over moonlight in adjusting Drosophila's activity pattern.

Schlichting M, Grebler R, Menegazzi P, Helfrich-Förster C.

J Biol Rhythms. 2015 Apr;30(2):117-28. doi: 10.1177/0748730415575245.

PMID:
25838418
28.

Memory integration: neural mechanisms and implications for behavior.

Schlichting ML, Preston AR.

Curr Opin Behav Sci. 2015 Feb;1:1-8.

29.

Photic entrainment in Drosophila assessed by locomotor activity recordings.

Schlichting M, Helfrich-Förster C.

Methods Enzymol. 2015;552:105-23. doi: 10.1016/bs.mie.2014.10.017. Epub 2014 Dec 26. Review.

PMID:
25707274
30.

Quantitative comparison of 21 protocols for labeling hippocampal subfields and parahippocampal subregions in in vivo MRI: towards a harmonized segmentation protocol.

Yushkevich PA, Amaral RS, Augustinack JC, Bender AR, Bernstein JD, Boccardi M, Bocchetta M, Burggren AC, Carr VA, Chakravarty MM, Chételat G, Daugherty AM, Davachi L, Ding SL, Ekstrom A, Geerlings MI, Hassan A, Huang Y, Iglesias JE, La Joie R, Kerchner GA, LaRocque KF, Libby LA, Malykhin N, Mueller SG, Olsen RK, Palombo DJ, Parekh MB, Pluta JB, Preston AR, Pruessner JC, Ranganath C, Raz N, Schlichting ML, Schoemaker D, Singh S, Stark CE, Suthana N, Tompary A, Turowski MM, Van Leemput K, Wagner AD, Wang L, Winterburn JL, Wisse LE, Yassa MA, Zeineh MM; Hippocampal Subfields Group (HSG).

Neuroimage. 2015 May 1;111:526-41. doi: 10.1016/j.neuroimage.2015.01.004. Epub 2015 Jan 14.

31.

Memory reactivation during rest supports upcoming learning of related content.

Schlichting ML, Preston AR.

Proc Natl Acad Sci U S A. 2014 Nov 4;111(44):15845-50. doi: 10.1073/pnas.1404396111. Epub 2014 Oct 20.

32.

CA1 subfield contributions to memory integration and inference.

Schlichting ML, Zeithamova D, Preston AR.

Hippocampus. 2014 Oct;24(10):1248-60. doi: 10.1002/hipo.22310. Epub 2014 Jun 11.

33.

Evaluating the agreement between tumour volumetry and the estimated volumes of tumour lesions using an algorithm.

Laubender RP, Lynghjem J, D'Anastasi M, Heinemann V, Modest DP, Mansmann UR, Sartorius U, Schlichting M, Graser A.

Eur Radiol. 2014 Jul;24(7):1521-8. doi: 10.1007/s00330-014-3195-9. Epub 2014 May 10.

PMID:
24816938
34.

Feature diagnosticity affects representations of novel and familiar objects.

Hsu NS, Schlichting ML, Thompson-Schill SL.

J Cogn Neurosci. 2014 Dec;26(12):2735-49. doi: 10.1162/jocn_a_00661. Epub 2014 May 6.

35.

Moonlight detection by Drosophila's endogenous clock depends on multiple photopigments in the compound eyes.

Schlichting M, Grebler R, Peschel N, Yoshii T, Helfrich-Förster C.

J Biol Rhythms. 2014 Apr;29(2):75-86. doi: 10.1177/0748730413520428.

PMID:
24682202
36.

FOLFOX4 with cetuximab vs. UFOX with cetuximab as first-line therapy in metastatic colorectal cancer: The randomized phase II FUTURE study.

Douillard JY, Zemelka T, Fountzilas G, Barone C, Schlichting M, Heighway J, Eggleton SP, Srimuninnimit V.

Clin Colorectal Cancer. 2014 Mar;13(1):14-26.e1. doi: 10.1016/j.clcc.2013.11.009. Epub 2013 Nov 16.

PMID:
24370353
37.

Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab.

Piessevaux H, Buyse M, Schlichting M, Van Cutsem E, Bokemeyer C, Heeger S, Tejpar S.

J Clin Oncol. 2013 Oct 20;31(30):3764-75. doi: 10.1200/JCO.2012.42.8532. Epub 2013 Sep 16.

PMID:
24043732
38.

Fly cryptochrome and the visual system.

Mazzotta G, Rossi A, Leonardi E, Mason M, Bertolucci C, Caccin L, Spolaore B, Martin AJ, Schlichting M, Grebler R, Helfrich-Förster C, Mammi S, Costa R, Tosatto SC.

Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):6163-8. doi: 10.1073/pnas.1212317110. Epub 2013 Mar 27.

39.

Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study.

Van Cutsem E, Tejpar S, Vanbeckevoort D, Peeters M, Humblet Y, Gelderblom H, Vermorken JB, Viret F, Glimelius B, Gallerani E, Hendlisz A, Cats A, Moehler M, Sagaert X, Vlassak S, Schlichting M, Ciardiello F.

J Clin Oncol. 2012 Aug 10;30(23):2861-8. doi: 10.1200/JCO.2011.40.9243. Epub 2012 Jul 2.

PMID:
22753904
40.

Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab.

Tejpar S, Celik I, Schlichting M, Sartorius U, Bokemeyer C, Van Cutsem E.

J Clin Oncol. 2012 Oct 10;30(29):3570-7. doi: 10.1200/JCO.2012.42.2592. Epub 2012 Jun 25.

PMID:
22734028
41.

The hippocampus and inferential reasoning: building memories to navigate future decisions.

Zeithamova D, Schlichting ML, Preston AR.

Front Hum Neurosci. 2012 Mar 26;6:70. doi: 10.3389/fnhum.2012.00070. eCollection 2012.

42.

Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials.

Bokemeyer C, Van Cutsem E, Rougier P, Ciardiello F, Heeger S, Schlichting M, Celik I, Köhne CH.

Eur J Cancer. 2012 Jul;48(10):1466-75. doi: 10.1016/j.ejca.2012.02.057. Epub 2012 Mar 23.

PMID:
22446022
43.

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.

Van Cutsem E, Köhne CH, Láng I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, Schlichting M, Zubel A, Celik I, Rougier P, Ciardiello F.

J Clin Oncol. 2011 May 20;29(15):2011-9. doi: 10.1200/JCO.2010.33.5091. Epub 2011 Apr 18.

PMID:
21502544
44.

Color, context, and cognitive style: variations in color knowledge retrieval as a function of task and subject variables.

Hsu NS, Kraemer DJ, Oliver RT, Schlichting ML, Thompson-Schill SL.

J Cogn Neurosci. 2011 Sep;23(9):2544-57. doi: 10.1162/jocn.2011.21619. Epub 2011 Jan 25.

PMID:
21265605
45.

Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.

Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A, Celik I, Schlichting M, Koralewski P.

Ann Oncol. 2011 Jul;22(7):1535-46. doi: 10.1093/annonc/mdq632. Epub 2011 Jan 12.

46.

Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial).

Piessevaux H, Buyse M, De Roock W, Prenen H, Schlichting M, Van Cutsem E, Tejpar S.

Ann Oncol. 2009 Aug;20(8):1375-82. doi: 10.1093/annonc/mdp011. Epub 2009 May 22.

47.

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.

Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P.

N Engl J Med. 2009 Apr 2;360(14):1408-17. doi: 10.1056/NEJMoa0805019.

48.

Male-pattern baldness is common in men with X-linked recessive ichthyosis.

Axt-Gadermann M, Schlichting M, Küster W.

Dermatology. 2003;207(3):308-9.

PMID:
14571075
49.

Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study.

Chapuy MC, Pamphile R, Paris E, Kempf C, Schlichting M, Arnaud S, Garnero P, Meunier PJ.

Osteoporos Int. 2002 Mar;13(3):257-64.

PMID:
11991447
50.

[Heart rate frequency and constitutional features of high yielding dairy cows in intensively managed and environmentally protected pasture].

Steinhardt M, Thielscher HH, Ladewig J, Hoppe T, Schlichting MC, Smidt D.

Tierarztl Prax. 1994 Jun;22(3):221-9. German.

PMID:
8048030

Supplemental Content

Loading ...
Support Center